Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

House Trims 21st Century Cures Fat: Draft Bill Loses Half Its Weight

Executive Summary

New discussion draft drops controversial exclusivity extensions and some other lesser-known ideas that may have benefited FDA and sponsors, but some placeholders still need to be filled.

You may also be interested in...



Congressional ‘Cures’ Debate Shifts To FDA Funding

House Democrats say FDA will need more money to be able to handle the responsibilities in the draft bill, while the agency worries reviews could slow without more resources.

FDA Succession Planning Targeted In House Legislation

Hamburg’s departure from commissioner post seems to be proceeding smoothly; proposals in 21st Century Cures bill would mandate a similar process always be followed.

Will #Cures2015 Fix Twitter Promotion?

House 21st Century Cures discussion draft would adjust FDA promotion regulations for Twitter, requiring that information communicated through hyperlink be considered part of the original post.

Related Content

Topics

UsernamePublicRestriction

Register

PS056839

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel